Vir Biotechnology director receives RSUs and options grant

Vir Biotechnology director Ramy Farid reported routine equity compensation awards.

Accepted by SEC EDGAR 05/28/2026 - 07:24 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vir Biotechnology director Ramy Farid reported routine equity compensation awards. He received 8,000 shares of Common Stock as restricted stock units under the company’s equity incentive plan, bringing his direct holdings to 32,000 shares after the grant.

He was also granted a stock option for 16,000 shares of Common Stock at an exercise price of $9.10 per share. Both the RSUs and the option are scheduled to vest in full on May 27, 2027, and the option expires on May 26, 2036. These are compensation-related acquisitions, not open-market purchases.

Insights

Equity compensation analyst

Routine director equity awards with time-based vesting.

Vir Biotechnology granted director Ramy Farid 8,000 RSUs and an option for 16,000 shares at $9.10, all vesting in full on May 27, 2027. These are standard board compensation tools, not market transactions.

The filing shows Farid now directly holds 32,000 common shares plus this new option position. Because these awards are part of an equity incentive plan and not open-market buying or selling, they carry limited signaling value for the company’s short-term outlook.

Insider Trade Summary

Grant/Award: 24,000 shares

Grant/Award 2 txns

Insider Farid Ramy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,000	$0.00	$0.00
Grant/Award	Common Stock	8,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 16,000 options (Direct); Common Stock — 32,000 shares (Direct)

Footnotes (3)

1. F1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
2. F2. The RSUs will vest in full on May 27, 2027.
3. F3. The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

Key Figures

RSU grant size: 8,000 shares Shares held after RSU grant: 32,000 shares Option grant size: 16,000 shares +3 more

6 metrics

RSU grant size 8,000 shares Restricted stock units granted on May 27, 2026

Shares held after RSU grant 32,000 shares Common Stock directly held after acquisition

Option grant size 16,000 shares Stock option covering Common Stock

Option exercise price $9.10/share Exercise price for 16,000-share stock option

Vesting date May 27, 2027 Full vesting for RSUs and stock option

Option expiration May 26, 2036 Expiration date of stock option grant

Key Terms

restricted stock units (RSUs), Equity Incentive Plan, stock option, Common Stock

4 terms

restricted stock units (RSUs) financial

"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Equity Incentive Plan financial

"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

stock option financial

"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Common Stock financial

"Stock Option (Right to Buy) ... underlying security title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vir Biotechnology (VIR) director Ramy Farid receive in this Form 4?

Ramy Farid received 8,000 shares of Vir Biotechnology Common Stock as restricted stock units and a stock option for 16,000 shares. Both awards were granted as part of the company’s equity incentive plan, reflecting routine director compensation rather than open-market trading.

At what price can the new Vir Biotechnology (VIR) stock options be exercised?

The newly granted Vir Biotechnology stock options have an exercise price of $9.10 per share. They cover 16,000 shares of Common Stock and were awarded as part of an equity incentive plan, with vesting and exercisability scheduled together on a future date.

When do Ramy Farid’s new Vir Biotechnology (VIR) RSUs and options vest?

Both the 8,000 restricted stock units and the 16,000-share stock option granted to Ramy Farid vest in full on May 27, 2027. At that time, the RSUs convert to shares and the option becomes fully exercisable, subject to the plan’s usual conditions.

How many Vir Biotechnology (VIR) shares does Ramy Farid hold after this grant?

After the RSU grant, Ramy Farid directly holds 32,000 shares of Vir Biotechnology Common Stock. In addition, he holds a newly granted stock option covering 16,000 shares, which is scheduled to vest and become exercisable in full on May 27, 2027.

Is this Vir Biotechnology (VIR) Form 4 a market purchase or routine award?

This Form 4 reflects routine equity compensation awards, not a market purchase or sale. Farid received 8,000 RSUs and a 16,000-share stock option under Vir Biotechnology’s equity incentive plan, both vesting in 2027, with no cash-paid open-market transaction reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farid Ramy

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		A(1)		8,000(2)	A	$0	32,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.1	05/27/2026		A		16,000(3)		05/27/2027	05/26/2036	Common Stock	16,000	$0	16,000	D

Explanation of Responses:

1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

2. The RSUs will vest in full on May 27, 2027.

3. The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)